NTx is a leader in producing high quality extended length mRNA and saRNA transcripts. Its cell-free, continuous-flow process mitigates the typical development challenges by producing extended length material and helps accelerate pre-clinical candidates towards regulatory filings and clinical studies.

NIIMBL is a public-private partnership with the mission to accelerate biopharmaceutical innovation and support the development of standards that enable more efficient and rapid manufacturing capabilities. NIIMBL also educates and trains a world-leading biopharmaceutical manufacturing workforce, fundamentally advancing U.S. competitiveness in this industry. The National Meeting is open to members and federal stakeholders only and promises three days of engaging content and robust discussions led by industry experts and thought leaders across the biopharmaceutical ecosystem.

At the conference, Dr. Nathan Duval, Lead Scientist at NTx will present the following:

• Lighting Presentation on NTx: Small and Medium Manufacturer Showcase
  • Tuesday, July 26 at 10am ET
  • Grand Ballroom C&D
• “Advanced Continuous Flow Manufacturing of mRNA Vaccines: Accelerating the Next Generation of RNA Product Development”
  • Tuesday, July 26 at 1:30pm ET
  • Falling Flowers Gallery Level 2 (posters will be displayed electronically)

To see the full conference schedule and register for the conference, please click here.

Dr. Alex Koglin, co-founder, and CEO of NTx will also attend the conference. To set up a meeting with the NTx team at the conference, please email info@ntxbio.com.

To learn more about NTx and its proprietary platform, please visit: https://www.ntxbio.com.

About NTx
Nature’s Toolbox, Inc. (NTx) is a life sciences company located in Rio Rancho, New Mexico. The company is commercializing its biomanufacturing systems NTxpress®, NTxscribe® and the bioinformatics platform, DruID, for the discovery of natural products. NTx’s proprietary continuous-flow, fully recombinant, in vitro, cell-free transcription system utilizes hollow fiber bioreactors to support the growing demand for mRNA-based vaccines and therapeutics. NTx’s biomanufacturing processes can easily be scaled to meet fluctuating supply needs so that companies can increase and streamline production as they respond to changing global demands. For more information, please visit: https://www.ntxbio.com